{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-047584","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2026-07-08T11:03:56+00:00","discovered_at":"2026-07-08T11:05:00.271830+00:00","generated_at":"2026-07-08T11:05:06.683356+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid Therapeutics appoints Charles Carter as CFO, replacing Jeffrey Rona","bullets":["CFO Jeffrey Rona departed July 6, 2026; no disagreement with company on accounting or financial reporting.","Charles Carter appointed CFO, SVP of Finance since Oct 2024; previously CFO at CERo Therapeutics and iCAD.","Carter receives $460k base salary, 35% target bonus, 50,000 RSUs vesting over 2 years, plus $75k bonus opportunity.","Rona receives 12 months base salary severance, prorated 2026 bonus, COBRA for 12 months, and consulting role through Dec 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-047584","json":"https://secwatch.observer/filing/0001628280-26-047584.json","markdown":"https://secwatch.observer/filing/0001628280-26-047584.md","text":"https://secwatch.observer/filing/0001628280-26-047584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026047584/0001628280-26-047584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026047584/ovid-20260707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-08T11:05:06.683356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}